- Email: [email protected]
8. Hepato-Biliary Unit, Prince of Wales Hospital, Shatin, Hong Kong
HPB 2000
Vo lume 2, Number 334 1- 342
HPB CLINICS AROUND THE WORLD
HPB
CLINICS
8. Hepato-Biliary Unit, Prince of Wales Hospital, Shatin, Hong Kong WYLau
Hepatome team: A = radiologist; B = pathologist, C, E, F, L = surgeons (including WY Lau, C); D, I.J. K The hepatologist is absent from the photograph.
= oncologists; G = physicist; H = research nurse.
Since its inception in 1984, the policy and objecti ves of the
The U ni t comprises a stro ng tea m of 15 surgeons. It
Hepato-B iliary Unit in the Department of S urgery at the Prince of Wales Hospital are to prov ide a comprehensive clinical service in the specialty, to strive continuously for
serves as a tertiary spec ialist refer ral centre for a popu lation of 2.5 million . The current spec ified 63-bed surgical wards are always fu lly utilised. There are 6 general and spec ialist
improved q uality, to care for patients to the best of our abi lities and to pursue research actively to improve cl inical
surgical outpatient clinics and 10 operating sessions per week. Total number of patients turnover i about 110 inpatients and 300 out-pati ents per week.
outcomes.
COITespondence to: Professor WY Lou. Chairman, Hepato-Biliary
© 2000 Isis Medical Media Ltd.
Unit, Prince of Wales Hospital, Shatin. Hong Kong
341
WY Lou
Due to the high prevalence of hepatitis B and its sequalae (cirrhos is, liver failure, hepatoce llular carcinoma (HCC ), and complications from portal hypertension), the
the Unit is able to provide a comprehensive service for various biliary tract disorders. The Unit is linked in its research activities with the
Unit is performing on average 2 orthotopic li ver transplantations per month (number largely limited by donor graft ava ilability), and see ing more than 500 new cases of HCC
Department of Onco logy, The C hinese University of Hong Kong. Well-equipped laboratories are situated in the Cancer Research C entre at the Prince of Wales H ospital. Active
a year. The dedicated Joint Hepato ma C linic is the first of its kind catering for HCC in the region in which oncolo-
research programmes, both basic and applied, are pursued. Work on serum tumour markers has contributed to the dif-
gists, physici ans, radiolog ists and surgeons work together. Liver resection , transplantation and local ablative therapy are the active treatment options in our Unit. For the umesectable and non-transplantable cases , the Unit has been the pion eer in using selecti ve internal irradi ati on (SIR) with Yttrium-90 particles , and syste mic immun o-
ferentiation of non-spec ific elevati on of alpha-fetoprote in in cirrhotic patients from patients having HCC by identification of the tumour-specific isoforms of alpha-fetoprotein. Cytogenetic studies have identifi ed different patterns of
ch emotherapy of regimen PIA F (cisplatin, interferon,
chromosomal aberration in HC C s with different aetiologies. N ovel genetic sequences are being identified by molecular techniques with the perspective of identifying
Adriamycin, 5-FU) . The preliminary experience showed that these two modalities of treatment offer a 20% chance of rendering umesectable cases resectable. O ther than
clinically important oncogenes or tumour suppressor genes. Other proj ects include bio-artificial liver support systems, stud y of Kupffer cell kinetics in the cirrhotic live r, the
HCC, cholangiocarcinoma, carcinoma of the gallbladd er and carcinoma of the pancreas are the other common malignancies seen in this Unit. Among benign diseases,
impact of growth hormone on liver regeneration after partial hepatectomy in a cirrhotic model, control of recurrent viral infection in liver transplant rec ipients by immunopro-
choledoch olithias is and h epatolithias is are co mmonly encountered. Because of a 24-hour on-ca ll ERC P service
phylax is and antiviral therapy, and study of MRI spectrometric patterns of the liver after partial hepatectomy and orthotopic liver transplantation.
342
Vo lume 2, Number 334 1- 342
HPB CLINICS AROUND THE WORLD
HPB
CLINICS
8. Hepato-Biliary Unit, Prince of Wales Hospital, Shatin, Hong Kong WYLau
Hepatome team: A = radiologist; B = pathologist, C, E, F, L = surgeons (including WY Lau, C); D, I.J. K The hepatologist is absent from the photograph.
= oncologists; G = physicist; H = research nurse.
Since its inception in 1984, the policy and objecti ves of the
The U ni t comprises a stro ng tea m of 15 surgeons. It
Hepato-B iliary Unit in the Department of S urgery at the Prince of Wales Hospital are to prov ide a comprehensive clinical service in the specialty, to strive continuously for
serves as a tertiary spec ialist refer ral centre for a popu lation of 2.5 million . The current spec ified 63-bed surgical wards are always fu lly utilised. There are 6 general and spec ialist
improved q uality, to care for patients to the best of our abi lities and to pursue research actively to improve cl inical
surgical outpatient clinics and 10 operating sessions per week. Total number of patients turnover i about 110 inpatients and 300 out-pati ents per week.
outcomes.
COITespondence to: Professor WY Lou. Chairman, Hepato-Biliary
© 2000 Isis Medical Media Ltd.
Unit, Prince of Wales Hospital, Shatin. Hong Kong
341
WY Lou
Due to the high prevalence of hepatitis B and its sequalae (cirrhos is, liver failure, hepatoce llular carcinoma (HCC ), and complications from portal hypertension), the
the Unit is able to provide a comprehensive service for various biliary tract disorders. The Unit is linked in its research activities with the
Unit is performing on average 2 orthotopic li ver transplantations per month (number largely limited by donor graft ava ilability), and see ing more than 500 new cases of HCC
Department of Onco logy, The C hinese University of Hong Kong. Well-equipped laboratories are situated in the Cancer Research C entre at the Prince of Wales H ospital. Active
a year. The dedicated Joint Hepato ma C linic is the first of its kind catering for HCC in the region in which oncolo-
research programmes, both basic and applied, are pursued. Work on serum tumour markers has contributed to the dif-
gists, physici ans, radiolog ists and surgeons work together. Liver resection , transplantation and local ablative therapy are the active treatment options in our Unit. For the umesectable and non-transplantable cases , the Unit has been the pion eer in using selecti ve internal irradi ati on (SIR) with Yttrium-90 particles , and syste mic immun o-
ferentiation of non-spec ific elevati on of alpha-fetoprote in in cirrhotic patients from patients having HCC by identification of the tumour-specific isoforms of alpha-fetoprotein. Cytogenetic studies have identifi ed different patterns of
ch emotherapy of regimen PIA F (cisplatin, interferon,
chromosomal aberration in HC C s with different aetiologies. N ovel genetic sequences are being identified by molecular techniques with the perspective of identifying
Adriamycin, 5-FU) . The preliminary experience showed that these two modalities of treatment offer a 20% chance of rendering umesectable cases resectable. O ther than
clinically important oncogenes or tumour suppressor genes. Other proj ects include bio-artificial liver support systems, stud y of Kupffer cell kinetics in the cirrhotic live r, the
HCC, cholangiocarcinoma, carcinoma of the gallbladd er and carcinoma of the pancreas are the other common malignancies seen in this Unit. Among benign diseases,
impact of growth hormone on liver regeneration after partial hepatectomy in a cirrhotic model, control of recurrent viral infection in liver transplant rec ipients by immunopro-
choledoch olithias is and h epatolithias is are co mmonly encountered. Because of a 24-hour on-ca ll ERC P service
phylax is and antiviral therapy, and study of MRI spectrometric patterns of the liver after partial hepatectomy and orthotopic liver transplantation.
342